Min Bao, MD

Kali Therapeutics
San Mateo, California, United States

Dr. Min Bao is the Chief Medical Officer and Confounder at Kali Therapeutics in the US. Prior to that she was the SVP of Clinical Development at AnaptysBio and Alpine Immune Sciences (acquired by Vertex Pharmaceuticals) after her last role as Global Development Lead at Genentech/Roche. During her 22-year tenure at Genentech/Roche, she developed diversified drug development skills across multiple therapeutic areas. She contributed and led activities from pre-IND to global approvals in autoimmune diseases and severe COVID-19. Min received her MD from Suzhou Medical College and Master of Science in Immunology from the University of Calgary.

Presentation(s):

• 0011: KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Alpine Immune Sciences, a Vertex Company: Employee (Terminated, August 31, 2024); AnaptysBio: Employee (Terminated, March 31, 2025)

• 0012: KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Alpine Immune Sciences, a Vertex Company: Employee (Terminated, August 31, 2024); AnaptysBio: Employee (Terminated, March 31, 2025)